Vaccine compositions and methods

1 . A pharmaceutical composition comprising an adjuvant combined with one or more antigens, wherein the adjuvant comprises living immune cells where at least a portion are activated T-cells and administration of the composition to a host generates a Th-1 response.

2 . The composition of claim 1 wherein the T-cells are memory T-cells of the Th-1 phenotype.

3 . The composition of claim 1 wherein the T-cells are activated by the cross-linking of CD3 and CD28 surface molecules on the T-cells.

4 . The composition of claim 1 wherein the activated T-cells express CD40L.

5 . The composition of claim 1 wherein the T-cells are allogeneic to the host.

6 . The composition of claim 1 wherein at least two antigens are combined with the adjuvant.

7 . The composition of claim 1 wherein the one or more antigens are from an antigen source selected from whole cells, organisms, lysates of whole cells or organisms, naked DNA or RNA, nuclear materials, peptides or proteins, antibodies, antigen pulsed or transfected dendritic cells.

8 . The composition of claim 1 wherein the one or more antigens comprises one or more tumor associated antigens.

9 . The composition of claim 1 wherein the one or more antigens comprises one or more heat shock proteins.

10 . The composition of claim 1 wherein the source of one or more antigens is a malignant tumor.

11 . The composition of claim 1 wherein the source of the one or more antigens is from a pathogen.

12 . An adjuvant composition comprising living immune cells wherein at least a portion of the immune cells are activated T-cells and wherein the administration of the adjuvant composition to a host elicits a Th-1 immune response.

13 . The composition of claim 12 wherein the T-cells are activated by cross-linking of the CD3 and CD28 surface molecules on the T-cells.

14 . The composition of claim 12 wherein the T-cells express CD40L.

15 . A method of making a pharmaceutical composition comprising:

preparing an adjuvant comprising living immune cells wherein the immune cells comprise at least a portion of T-cells; and

combining one or more antigens with the adjuvant, wherein the pharmaceutical composition, upon administration to a host, stimulates an immune response in the host.

16 . The method of claim 15 wherein the adjuvant and the one or more antigens are combined prior to administration to the host.

17 . The method of claim 15 wherein the immune response generated is a Th1 response.

18 . The method of claim 15 wherein the T-cells are memory T-cells of the Th-1 phenotype.

19 . The method of claim 15 wherein the T-cells are activated T-cells.

20 . The method of claim 15 wherein the T-cells are activated by the cross-linking of CD3 and CD28 surface molecules on the T-cells.

21 . The method of claim 15 wherein the activated T-cells express CD40L.

22 . The method of claim 15 wherein the T-cells are allogeneic to the host.

23 . The method of claim 15 wherein at least two antigens are combined with the adjuvant.

24 . The method of claim 15 wherein the one more antigens are selected from one or more antigenic sources.

25 . The method of claim 15 wherein the antigenic sources are selected from whole cells, organisms, lysates of whole cells or organisms, naked DNA or RNA, nuclear materials, antibodies, antigen pulsed or transfected dendritic cells.

26 . The method of claim 15 wherein the one or more antigens are tumor associated antigens.

27 . The method of claim 15 wherein the one or more antigens are heat shock proteins.

28 . The method of claim 15 wherein the one or more antigens is from a malignant tumor.

29 . The method of claim 15 wherein the one or more antigens are from a disease causing agent.

30 . A method of reducing antigens related to or causing a disease in a host comprising:

administering a pharmaceutical composition comprising an adjuvant and one or more antigens, the adjuvant comprising living immune cells wherein the immune cells comprise at least a portion of T-cells, and wherein the pharmaceutical composition, upon administration to the host, stimulates an immune response in the host.

31 . The method of claim 30 wherein the T-cells are activated T-cells.

32 . The method of claim 30 wherein the activated T-cells express CD40L.

33 . The method of claim 30 wherein the T-cells are allogeneic to the host.

34 . The method of claim 30 wherein the pharmaceutical composition includes at least two antigens.

35 . The method of claim 30 wherein the one or more antigens are tumor associated antigens.

36 . The method of claim 30 wherein the one or more antigens are heat shock proteins.

37 . The method of claim 30 wherein the one or more antigens are from a malignant tumor.

38 . The method of claim 30 wherein the one or more antigens are from a disease causing antigen.

39 . The method of claim 30 further comprising administering a booster composition.

40 . The method of claim 39 wherein the booster comprises living immune cells wherein at least a portion are activated T-cells.

41 . The method of claim 39 wherein the booster comprises living immune cells wherein at least a portion are activated T-cells and one or more antigens.

42 . The method of claim 30 wherein the adjuvant and the one or more antigens are combined prior to administering to the host.

43 . The method of claim 30 wherein the adjuvant and the one or more antigens are administered sequentially to the host.

44 . A method of treating a disease in a patient comprising administering a pharmaceutical composition comprising an adjuvant and one or more antigens, the adjuvant comprising living immune cells wherein the immune cells comprise at least a portion of T-cells, and wherein the pharmaceutical composition, upon administration to the patient, stimulates an immune response in the host.

45 . The method of claim 44 wherein the T-cells are activated T-cells.

46 . The method of claim 44 wherein the disease is a cancer.

47 . The method of claim 44 wherein the disease is caused by an infectious pathogen.